UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): November 2527, 2024

Molecular Templates, Inc.

(Exact name of registrant as specified in its charter)

Delaware	001-32979	94-3409596
(State or other jurisdiction of incorporation or organization)	(Commission File Number)	(I.R.S. Employer Identification No.)
(State or other jurisdiction ofincorporation or organization)	(CommissionFile Number)	(I.R.S. EmployerIdentification No.)

9301 Amberglen Blvd, Suite 100

Austin, Texas 78729

(Address of Principal Executive Offices) (Zip Code)

Registrant’s telephone number, including area code: (512) 869-1555

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		~~Trading symbol~~Tradingsymbol(s)		Name of each ~~exchange~~exchangeon on which registered
Common Stock, $0.001 par value per share		MTEM		The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 35.0102 ~~Notice~~Departure of ~~Delisting~~Directors or ~~Failure~~Certain toOfficers; ~~Satisfy~~Election aof ~~Continued~~Directors; ~~Listing~~Appointment ~~Rule~~of orCertain ~~Standard~~Officers; ~~Transfer~~Compensatory Arrangements of ~~Listing~~Certain Officers.

OnResignation ~~November 25,~~of ~~2024,~~Chief ~~Molecular~~Financial ~~Templates,~~Officer Inc. (the “Company”) received a written notice (the “First Notice”) from the Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company is not in compliance with Nasdaq Listing Rules because the Company has not yet filed its Quarterly Report on Form 10-Q for the fiscal quarter ended September 30, 2024 (the “Delinquent Filing”). Specifically, Nasdaq Listing Rule 5250(c)(1) requires listed companies to timely file all required periodic financial reports with the Securities and Exchange Commission.

InOn ~~accordance~~November 27, ~~with~~2024, Jason Kim notified the ~~First~~Company ~~Notice,~~of his decision to resign from his position as the Company’s ~~has~~President, ~~until~~Chief ~~January 24~~Financial Officer and Treasurer, ~~2025~~effective toas ~~submit~~of aDecember 8, ~~plan~~2024, toin ~~regain~~which ~~compliance~~positions ~~with~~he ~~respect~~serves toas the ~~Delinquent~~Company’s ~~Filing~~principal ~~(the~~financial ~~“Plan”)~~officer and principal accounting officer. IfHis ~~Nasdaq~~decision ~~accepts~~to resign was not the ~~Plan,~~result of any ~~exception~~disagreement ~~granted~~with bythe Company, the ~~Nasdaq~~Company’s ~~staff~~management toor ~~allow~~any member of the Company’s toBoard ~~regain~~of ~~compliance~~Directors, ifor ~~granted~~on any matter relating to the Company’s operations, policies, or practices. Mr. Kim will benot ~~limited~~receive toseverance apayments ~~maximum~~or continuation of ~~180~~health ~~calendar~~benefits, ~~days~~pursuant ~~from~~to ~~the~~his ~~due~~amended ~~date~~and ofrestated executive employment agreement with the ~~Delinquent~~Company ~~Filing~~dated April 22, or2016 ~~May~~and mutual release agreement dated December 192, ~~2025.~~2024 If(the ~~Nasdaq~~“Release ~~does~~Agreement”). ~~not~~Pursuant ~~accept~~to the ~~Company’s~~Release ~~Plan~~Agreement, ~~the~~outstanding ~~Company~~options ~~will~~to ~~have~~purchase ~~the~~19,504 ~~opportunity~~shares toof ~~appeal~~the ~~that~~Company’s ~~decision~~common tostock apreviously ~~Hearings~~granted ~~Panel~~to Mr. Kim ~~The~~will ~~Company~~continue ~~has~~to ~~not~~vest ~~yet~~and ~~determined~~become ~~whether~~exercisable orduring ~~not~~the itTransition ~~intends~~Period to(as ~~appeal~~defined orbelow) ~~submit~~in aaccordance ~~plan~~with oftheir ~~compliance~~terms.

On ~~November~~December 252, 2024, the Company ~~received~~and ~~another~~Mr. Kim ~~written~~entered ~~notice~~into ~~(the~~a ~~“Second~~Consulting ~~Notice;”~~Agreement ~~together with~~ (the ~~First Notice, the~~ “~~Notices~~Consulting Agreement”.), ~~from~~pursuant ~~Nasdaq~~to ~~notifying~~which ~~the~~Mr. Kim ~~Company~~agreed ~~that,~~to ~~for~~provide ~~the~~consulting ~~preceding~~and 30advisory ~~consecutive~~services ~~business~~to ~~days,~~ the ~~bid~~Company ~~price~~on ofa ~~the~~transitional ~~Company’s~~basis ~~common~~until ~~stock~~December 31, ~~par~~2024 ~~value $0.001 per share~~ (the “~~Common~~Transition ~~Stock~~Period”),. ~~closed below the minimum $1~~Mr.00 Kim ~~per~~will ~~share~~not ~~requirement~~receive ~~for~~separate ~~continued~~compensation ~~inclusion~~in ~~under~~connection ~~Nasdaq~~with ~~Listing Rule 5550(a)(2) (~~the ~~“Minimum~~Consulting ~~Bid Price Requirement”)~~Agreement.

InAppointment accordance with Nasdaq rules, the Company has been provided a 180-calendar day compliance period, or until May 26, 2025 (the “Compliance Date”), to regain compliance with the Minimum Bid Price Requirement. To regain compliance with the Minimum Bid Price Requirement, the closing bid price of ~~the~~Interim ~~Common~~Chief ~~Stock~~Financial ~~must~~Officer meet or exceed $1.00 per share for a minimum of ten consecutive business days during the 180-calendar day compliance period. Pursuant to Nasdaq Listing Rule 5810(c)(3)(A)(iii), if the price of the Common Stock is less than $0.10 during a compliance period, Nasdaq will issue a delisting determination for the Common Stock.

IfOn ~~the~~December 3, ~~Company~~2024, ~~is not in compliance with~~ the ~~Minimum~~Board ~~Bid~~appointed ~~Price~~Eric ~~Requirement~~Poma, byPh.D., ~~the~~age ~~Compliance Date~~52, the Company’s ~~may~~current ~~qualify~~Chief ~~for~~Executive aOfficer, ~~second~~Chief ~~180-calendar~~Scientific ~~day~~Officer ~~compliance~~and ~~period.~~member Toof ~~qualify~~the ~~for~~Board ~~this~~of ~~additional~~Directors ~~compliance~~of ~~period,~~ the Company, ~~will~~as ~~be required to meet~~ the ~~continued~~Company’s ~~listed~~Interim ~~requirement~~Chief ~~for~~Financial ~~market~~Officer ~~value of publicly held shares~~ and ~~all other initial listing standards for the Nasdaq Capital Market~~Treasurer, ~~with~~effective ~~the~~as ~~exception~~ of ~~the~~Mr. ~~Minimum~~Kim’s ~~Bid~~resignation. ~~Price~~In ~~Requirement~~this role, ~~and~~Dr. Poma ~~must~~will ~~notify~~serve ~~Nasdaq~~as inthe ~~writing~~Company’s ofprincipal ~~its~~financial ~~intention~~officer toand ~~cure~~principal ~~the~~accounting ~~deficiency during the second compliance period~~officer.

IfDr. Poma ~~the~~has ~~Company~~been ~~does~~a ~~not~~member ~~regain~~of ~~compliance with~~ the ~~Minimum~~board ~~Bid~~of ~~Price~~directors ~~Requirement~~of by the ~~Compliance~~Company ~~Date~~since ~~and~~August is2017. ~~not~~In ~~eligible~~February ~~for~~2009, anDr. Poma ~~additional~~founded ~~compliance~~Threshold ~~period~~Pharmaceuticals, atInc., ~~that~~an ~~time,~~accounting ~~Nasdaq~~predecessor ~~will~~of ~~provide~~the ~~written~~Company, ~~notification~~serving toon ~~the~~its ~~Company~~board ~~that~~of directors since its ~~Common~~inception. ~~Stock~~From ~~will~~March be2005 ~~subject~~until toSeptember ~~delisting~~2008, Dr. Poma Atwas ~~that~~Vice ~~time,~~President ~~the~~of ~~Company~~Business ~~may~~Development ~~appeal~~of ~~the~~Innovive ~~delisting~~Pharmaceuticals, ~~determination~~Inc. to(acquired aby ~~Nasdaq~~Cytrx ~~Hearing~~Corporation), ~~Panel~~a biotechnology company. ~~There~~As ~~can~~the befounder noof ~~assurance~~Threshold ~~that~~Pharmaceuticals ~~the~~and ~~Company~~in ~~will~~his ~~regain~~role ~~compliance~~as orChief ~~otherwise~~Scientific ~~maintain~~Officer, ~~compliance~~he ~~with~~led ~~any~~the invention of technology underlying the ~~other~~Company’s ~~listing~~platform ~~requirements~~technology. ~~The~~Dr. Poma ~~Company~~received ~~has~~his ~~not~~Ph.D. ~~yet~~in ~~determined~~Microbiology ~~whether~~and orImmunology ~~not~~and itB.S. ~~intends~~in toBiology ~~appeal~~from orthe toUniversity ~~take~~of ~~any~~North ~~other~~Carolina ~~action~~at inChapel ~~response~~Hill toand ~~the~~his ~~Second~~M.B.A. ~~Notice~~from New York University.

2No new compensatory arrangements have been entered into at this time with Dr. Poma in connection with him assuming the responsibilities as the Company’s Interim Chief Financial Officer and Treasurer. There are no family relationships between Dr. Poma and any director or executive officer of the Company, and there are no relationships or understandings between Dr. Poma and any other person pursuant to which he was appointed as the Interim Chief Financial Officer and Treasurer. Dr. Poma does not have any direct or indirect material interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K.

The Notices have no immediate effect on the listing of the Company’s shares.

Item 5.07 Submission of Matters to a Vote of Security Holders.

The information disclosed in Item 8.01 of this Current Report on Form 8-K is incorporated herein by reference.

Item 8.01 Other Events.

On November 26, 2024, the Company convened its special meeting of stockholders (the “Special Meeting”) for the purpose of approving the dissolution of the Company and the Plan of Liquidation and Dissolution (the “Dissolution Proposal”). The Special Meeting was adjourned without any business being conducted in order to allow time to achieve a quorum and allow the Company’s stockholders additional time to vote on the Dissolution Proposal.

The adjourned Special Meeting is scheduled to reconvene on December 4, 2024 at 10:00 a.m., Eastern Time in a virtual format. Stockholders should visit https://web.viewproxy.com/mtem/2024 for information about accessing the reconvened meeting. The close of business on October 15, 2024 will continue to be the record date for the determination of stockholders of the Company entitled to vote at the Special Meeting. Stockholders of the Company who have previously submitted their proxy or otherwise voted do not need to take any action.

No changes have been made in the proposals to be voted on by stockholders at the Special Meeting. The Company encourages all of its stockholders to read the Proxy Statement, which is available free of charge on the SEC website at www.sec.gov.

During the period of adjournment, the Company will continue to solicit votes from its stockholders with respect to the proposals set forth in the Proxy Statement. The Company encourages all stockholders who have not yet voted to do so promptly. As of October 15, 2024, the Company had 6,583,880 shares of Common Stock issued and outstanding.

Forward-Looking Statements

Certain statements made in this Current Report on Form 8-K are “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. The words “estimates,” “projected,” “expects,” “anticipates,” “forecasts,” “plans,” “intends,” “believes,” “seeks,” “may,” “will,” “should,” “future,” “propose” and variations of these words or similar expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements. Such forward-looking statements include but are not limited to statements regarding the date of the Company’s reconvened special meeting of stockholders and the Company obtaining the requisite stockholder vote to approve the Dissolution Proposal, the Company’s ability to maintain the listing of its Common Stock on the Nasdaq Capital Market and whether the Company may make appeals, submit plans of compliance or take other such similar actions with respect to the Nasdaq listing. These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of significant known and unknown risks, uncertainties, assumptions, and other important factors, many of which are outside the Company’s control, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. Important factors, among others that may affect actual results or outcomes, include risks and uncertainties disclosed from time to time in the Company’s filings with the SEC, including those under the heading “Risk Factors” in the Company’s latest annual report on Form 10-K filed on March 29, 2024 (as amended on April 25, 2024) and in its subsequent reports. You are cautioned not to place undue reliance on forward-looking statements. All information herein speaks only as of the date hereof.

Additional Information and Where to Find It

In connection with the Special Meeting, the Company filed a definitive proxy statement (the “Proxy Statement”), with the U.S. Securities and Exchange Commission (the “SEC”) on October 28, 2024, which was mailed to the Company’s stockholders as of the record date for the special meeting of stockholders. STOCKHOLDERS AND OTHER INTERESTED PERSONS ARE ADVISED TO READ THE DEFINITIVE PROXY STATEMENT, AS WELL AS ANY AMENDMENTS THERETO, BECAUSE IT CONTAINS IMPORTANT INFORMATION ABOUT THE MATTERS BEFORE THE STOCKHOLDERS AT THE SPECIAL MEETING. The Company’s stockholders may also obtain copies of the Proxy Statement and all other relevant documents filed or that will be

filed with the SEC in connection with the Special Meeting, without charge, once available, at the SEC website at http://www.sec.gov or by directing a request to: Molecular Templates, Inc. at 9301 Amberglen Blvd, Suite 100, Austin, Texas 78729, Attention: Secretary.

Participants in the Solicitation

The Company and certain of its respective directors, executive officers and other members of management and employees may be deemed participants in the solicitation of proxies of the Company’s stockholders in connection with the Special Meeting. STOCKHOLDERS AND OTHER INTERESTED PERSONS MAY OBTAIN, WITHOUT CHARGE, MORE DETAILED INFORMATION REGARDING THE DIRECTORS AND OFFICERS OF THE COMPANY IN ITS ANNUAL REPORT ON FORM 10-K FOR THE FISCAL YEAR ENDED DECEMBER 31, 2023, WHICH WAS FILED WITH THE SEC ON MARCH 29, 2024 (AS AMENDED ON APRIL 25, 2024). INFORMATION REGARDING THE PERSONS WHO MAY, UNDER SEC RULES, BE DEEMED PARTICIPANTS IN THE SOLICITATION OF PROXIES TO STOCKHOLDERS IN CONNECTION WITH THE SPECIAL MEETING AND OTHER MATTERS TO BE VOTED AT THE SPECIAL MEETING ARE SET FORTH IN THE DEFINITIVE PROXY STATEMENT FOR THE SPECIAL MEETING.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Molecular Templates, Inc.

Dated: November 26, 2024

Dated: December 4, 2024

/s/ Eric E. Poma, Ph.D.

Name: Eric E. Poma, Ph.D.

Title: Chief Executive Officer

Filing Compare · Molecular Templates, Inc.